Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.
Ther Adv Musculoskelet Dis
washington; swedish; certolizumab pegol; disease control; psoriatic arthritis; treatment targets; work productivity
BACKGROUND: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA.
DESIGN: RAPID-PsA was a 216-week phase III trial.
RESULTS: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: >7.7, ACR20 to <50: >20.9,
Orthopedics & Sports Medicine
Tillett, William; Coates, Laura C; Kiri, Sandeep; Taieb, Vanessa; Willems, Damon; and Mease, Philip, "Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis." (2022). Articles, Abstracts, and Reports. 6781.